Serum Chemistry Profiling and Prognostication in Systemic Mastocytosis: a Registry-based Study of the ECNM and GREM

Certain laboratory abnormalities correlate with subvariants of systemic mastocytosis (SM) and are often prognostically relevant. To assess the diagnostic and prognostic value of individual serum chemistry parameters in SM, 2607 patients enrolled within the European Competence Network on Mastocytosis and 575 patients enrolled within the German Registry on Eosinophils and Mast Cells were analyzed. For screening and diagnosis of SM, tryptase was identified as the most specific serum parameter. For differentiation between indolent and advanced SM (AdvSM), the following serum parameters were most relevant: tryptase, alkaline phosphatase, β2-microglobulin, lactate dehydrogenase (LDH), albumin, vitamin B12, and C-reactive protein (P < .001). With regard to subvariants of AdvSM, an elevated LDH of ≥260 U/L was associated with multilineage expansion (leukocytosis, r = 0.37, P < .001; monocytosis, r = 0.26, P < .001) and the presence of an associated myeloid neoplasm (P < .001), whereas tryptase levels were highest in mast cell leukemia (MCL) vs non-MCL (308μg/L vs 146μg/L, P = .003). Based on multivariable analysis, the hazard-risk weighted assignment of 1 point to LDH (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.0; P = .018) and 1.5 points each to β2-microglobulin (HR, 2.7; 95% CI, 1.4-5.4; P = .004) and albumin (HR, 3.3; 95% CI, 1.7-6.5; P = .001) delineated a highly predictive 3-tier risk classification system (0 points, 8.1 years vs 1 point, 2.5 years; ≥1.5 points, 1.7 years; P < .001). Moreover, serum chemistry parameters enabled further stratification of patients classified as having an International Prognostic Scoring System for Mastocytosis-AdvSM1/2 risk score (P = .027). In conclusion, serum chemistry profiling is a crucial tool in the clinical practice supporting diagnosis and prognostication of SM and its subvariants.

Citing Articles

Management of Advanced Systemic Mastocytosis: Clinical Challenges.

Tremblay D, Wagner N, Mascarenhas J J Blood Med. 2024; 15:421-433.

PMID: 39279879 PMC: 11402342. DOI: 10.2147/JBM.S366367.

References

Lyons J . Hereditary Alpha Tryptasemia: Genotyping and Associated Clinical Features. Immunol Allergy Clin North Am. 2018; 38(3):483-495. PMC: 6411063. DOI: 10.1016/j.iac.2018.04.003. View

Sperr W, El-Samahi A, Kundi M, Girschikofsky M, Winkler S, Lutz D . Elevated tryptase levels selectively cluster in myeloid neoplasms: a novel diagnostic approach and screen marker in clinical haematology. Eur J Clin Invest. 2009; 39(10):914-23. DOI: 10.1111/j.1365-2362.2009.02184.x. View

Schwaab J, Cabral do O Hartmann N, Naumann N, Jawhar M, Weiss C, Metzgeroth G . Importance of Adequate Diagnostic Workup for Correct Diagnosis of Advanced Systemic Mastocytosis. J Allergy Clin Immunol Pract. 2020; 8(9):3121-3127.e1. DOI: 10.1016/j.jaip.2020.05.005. View

Arendt J, Sorensen H, Horsfall L, Petersen I . Elevated Vitamin B12 Levels and Cancer Risk in UK Primary Care: A THIN Database Cohort Study. Cancer Epidemiol Biomarkers Prev. 2019; 28(4):814-821. DOI: 10.1158/1055-9965.EPI-17-1136. View

Jawhar M, Schwaab J, Schnittger S, Sotlar K, Horny H, Metzgeroth G . Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. Leukemia. 2015; 29(5):1115-22. DOI: 10.1038/leu.2015.4. View

Vos B, van der Veer E, van Voorst Vader P, Mulder A, Van der Heide S, Arends S . Diminished reliability of tryptase as risk indicator of mastocytosis in older overweight subjects. J Allergy Clin Immunol. 2014; 135(3):792-8. DOI: 10.1016/j.jaci.2014.05.047. View

Valent P, Arock M, Bischoff S, Buhring H, Brockow K, Escribano L . The European Competence Network on Mastocytosis (ECNM). Wien Klin Wochenschr. 2005; 116(19-20):647-51. DOI: 10.1007/s00508-004-0253-3. View

Aberer E, Savic S, Bretterklieber A, Reiter H, Berghold A, Aberer W . Disease spectrum in patients with elevated serum tryptase levels. Australas J Dermatol. 2014; 56(1):7-13. DOI: 10.1111/ajd.12146. View

Gotlib J, Kluin-Nelemans H, Akin C, Hartmann K, Valent P, Reiter A . Practical management of adverse events in patients with advanced systemic mastocytosis receiving midostaurin. Expert Opin Biol Ther. 2020; 21(4):487-498. DOI: 10.1080/14712598.2021.1837109. View

10.

Lim K, Tefferi A, Lasho T, Finke C, Patnaik M, Butterfield J . Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009; 113(23):5727-36. DOI: 10.1182/blood-2009-02-205237. View

11.

Valent P, Akin C, Nedoszytko B, Bonadonna P, Hartmann K, Niedoszytko M . Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine. Int J Mol Sci. 2020; 21(23). PMC: 7731385. DOI: 10.3390/ijms21239030. View

12.

Valent P, Arock M, Bonadonna P, Brockow K, Broesby-Olsen S, Escribano L . European Competence Network on Mastocytosis (ECNM): 10-year jubilee, update, and future perspectives. Wien Klin Wochenschr. 2012; 124(23-24):807-14. DOI: 10.1007/s00508-012-0293-z. View

13.

Gavars D, Perminov D, Tauckels E, Lindenberga I, Auce A, Lejniece S . Association of elevated vitamin B with oncohematological diseases in a cohort of 79,524 patients from Latvia. Exp Oncol. 2019; 41(4):357-362. DOI: 10.32471/exp-oncology.2312-8852.vol-41-no-4.13930. View

14.

Sperr W, Kundi M, Alvarez-Twose I, van Anrooij B, Oude Elberink J, Gorska A . International prognostic scoring system for mastocytosis (IPSM): a retrospective cohort study. Lancet Haematol. 2019; 6(12):e638-e649. PMC: 7115823. DOI: 10.1016/S2352-3026(19)30166-8. View

15.

Jawhar M, Schwaab J, Hausmann D, Clemens J, Naumann N, Henzler T . Splenomegaly, elevated alkaline phosphatase and mutations in the SRSF2/ASXL1/RUNX1 gene panel are strong adverse prognostic markers in patients with systemic mastocytosis. Leukemia. 2016; 30(12):2342-2350. DOI: 10.1038/leu.2016.190. View

16.

Arock M, Sotlar K, Akin C, Broesby-Olsen S, Hoermann G, Escribano L . KIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on Mastocytosis. Leukemia. 2015; 29(6):1223-32. PMC: 4522520. DOI: 10.1038/leu.2015.24. View

17.

Valent P, Oude Elberink J, Gorska A, Lange M, Zanotti R, van Anrooij B . The Data Registry of the European Competence Network on Mastocytosis (ECNM): Set Up, Projects, and Perspectives. J Allergy Clin Immunol Pract. 2018; 7(1):81-87. PMC: 7115815. DOI: 10.1016/j.jaip.2018.09.024. View

18.

Hoermann G, Sotlar K, Jawhar M, Kristensen T, Bachelot G, Nedoszytko B . Standards of Genetic Testing in the Diagnosis and Prognostication of Systemic Mastocytosis in 2022: Recommendations of the EU-US Cooperative Group. J Allergy Clin Immunol Pract. 2022; 10(8):1953-1963. DOI: 10.1016/j.jaip.2022.03.001. View

19.

Freedman L . Tables of the number of patients required in clinical trials using the logrank test. Stat Med. 1982; 1(2):121-9. DOI: 10.1002/sim.4780010204. View

20.

Valent P, Horny H, Escribano L, Longley B, Li C, Schwartz L . Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001; 25(7):603-25. DOI: 10.1016/s0145-2126(01)00038-8. View